This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Women's Health, Other  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;293:2985-2989.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Orlando—Over the years, a number of clinical trials have proved the worth of targeted therapies for some patients with cancer, but the treatments have generally not been as effective as standard-of-care chemotherapy regimens.

Now, though, large clinical studies presented at the annual meeting of the American Society of Clinical Oncology held here in May have revealed that chemotherapy plus monoclonal antibodies against particular proteins involved in cancer progression offer improved progression-free and overall survival for women with early-stage or metastatic breast cancer compared with chemotherapy alone. The findings suggest that such targeted biologic agents could some day be considered a component of standard treatments in the fight against many forms of cancer.

METASTATIC BREAST CANCER

In an interim analysis of one National Cancer Institute trial (E2100), led by Eastern Cooperative Oncology Group researchers, the combination of weekly chemotherapy (paclitaxel) plus the monoclonal antibody bevacizumab as first-line treatment for women . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Genetic alterations in signaling pathways in melanoma.
Haluska et al.
Clin. Cancer Res. 2006;12:2301s-2307s.
ABSTRACT | FULL TEXT